By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – HealthLinx today said that Seoul Clinical Laboratories will distribute the firm's OvPlex diagnostic panel in South Korea.

SCL will begin distribution of the protein biomarkers-based test once it has received marketing approval from the South Korea Food and Drug Administration. HealthLinx said it is conducting a 220-patient study aimed at supporting its marketing application.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.